Physician profile
Anna Currid
NPI 1801212840
$676.59
in general payments reported to CMS, 2019-2025
13 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.35 · 2024: $403 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $236.62 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Kiniksa Pharmaceuticals International, Plc | $86.12 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.96 | 2024-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $52.21 | 2024-2025 | Verquvo |
| Pfizer INC. | $44.68 | 2025 | |
| Scpharmaceuticals INC. | $37.17 | 2024-2025 | |
| Cvrx, INC. | $27.94 | 2024 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $24.03 | 2024 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $19.79 | 2025 | Uptravi, Opsumit |
| Heartflow, INC. | $19.53 | 2024 | |
| Novo Nordisk INC | $14.75 | 2024 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $14.44 | 2024 | Farxiga |
| Astellas Pharma US INC | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Currid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.